• RA Capital Management bought 32,876 Artiva Biotherapeutics common shares in open-market purchases at about USD 8.88 to USD 8.98.
• RA Capital Healthcare Fund’s stake rose to 16,795,919 shares held indirectly through the fund structure.
• The filing shows additional indirect holdings across affiliated RA Capital vehicles, including 826,832 shares in Nexus Fund III.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001231919-26-000711), on June 29, 2026, and is solely responsible for the information contained therein.